PDS Planning’s Antares Pharma, Inc. ATRS Stock Holding History

PDS Planning’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-12,000	Closed	-$33K	–	145
2020 Q2	$33K	Hold	12,000	–	–	0.02%	133
2020 Q1	$28K	Hold	12,000	–	–	0.02%	100
2019 Q4	$56K	Hold	12,000	–	–	0.04%	102
2019 Q3	$40K	Hold	12,000	–	–	0.03%	97
2019 Q2	$39K	Hold	12,000	–	–	0.03%	92
2019 Q1	$36K	Hold	12,000	–	–	0.03%	86
2018 Q4	$33K	Buy	+12,000	New	+$39.5K	0.03%	80
2018 Q3	–	Sell	-12,000	Closed	-$31K	–	84
2018 Q2	$31K	Hold	12,000	–	–	0.03%	73
2018 Q1	$26K	Hold	12,000	–	–	0.03%	72
2017 Q4	$24K	Buy	+12,000	New	+$26.1K	0.02%	65

Other funds holding ATRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

PDS Planning's ATRS Position: Q3 2020 in Review

PDS Planning sold out of Antares Pharma, Inc. (ATRS) in Q3 2020, closing a stake of 12,000 shares — an estimated $33K sold.

PDS Planning first reported a position in ATRS in Q4 2017 and held it in 10 quarters. The position peaked at $56K in Q4 2019. 164 funds tracked by Wall St. Rank hold ATRS as of Q3 2020.

PDS Planning reported no remaining Antares Pharma, Inc. position as of Q3 2020 after selling out during the quarter.
PDS Planning sold 12,000 Antares Pharma, Inc. shares in Q3 2020, an estimated $33K.
PDS Planning first reported a position in Antares Pharma, Inc. in Q4 2017 and held it in 10 quarters.
PDS Planning's Antares Pharma, Inc. position peaked at $56K in Q4 2019.
164 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q3 2020.

Based on PDS Planning's 13F filing for Q3 2020, filed 19 Oct 2020.